HIV Infections Clinical Trial
— TRIMOfficial title:
Feasibility and Acceptability of a Barbershop Based HIV Prevention Initiative Among Heterosexual Men in Kalangala Islands, Uganda: A Cluster Randomized Trial
Verified date | April 2024 |
Source | HIV Prevention Trials Network |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To test community-based approaches to engage heterosexual men at risk for HIV and specifically to assess the feasibility and acceptability of a barbershop based HIV prevention program.
Status | Enrolling by invitation |
Enrollment | 250 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: Persons who identify as a heterosexual male and meet all of the following criteria are eligible for inclusion in this study: 1. Age = 16 years a. Any participants 16-17 years old will be enrolled following the Uganda National Council for Science and Technology (UNCST) guidelines for mature and emancipated minors 2. Able and willing to provide informed consent 3. Behaviorally vulnerable to HIV, based on self-report of at least one of the following in the last three months: 1. Had condomless sex with a person of unknown HIV status or a person living with HIV 2. Had more than one sexual partner 4. HIV negative per Ugandan Ministry of Health guidelines and the Study-specific Procedures (SSP) Manual 5. Is a regular customer at a participating barbershop as defined in the SSP Manual Exclusion Criteria: Persons who meet any of the following criteria will be excluded from this study: 1. Not planning to stay in the study catchment area in the next 12 months 2. Any other condition that in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. Participants who report sex with other men will not be excluded from this study so long as they meet the inclusion and exclusion criteria listed above. |
Country | Name | City | State |
---|---|---|---|
Uganda | MU-JHU Research Collaboration (MUJHU CARE LTD) CRS | Kampala |
Lead Sponsor | Collaborator |
---|---|
HIV Prevention Trials Network | Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative | Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Participant responses from surveys at Week 26 and Week 52 about acceptability of the intervention | Week 26 and Week 52 | |
Primary | To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative | Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Barber responses from surveys about feasibility and acceptability of intervention | Week 13, Week 26, Week 39, Week 52, Week 65 | |
Primary | To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative | Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Recruitment rates during enrollment and retention in study and barbershop activities at Week 26 and Week 52 | Week 26 and Week 52 | |
Primary | To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative | Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Frequency of barber-participant interactions | Week 13, Week 26, Week 39, Week 52, Week 65 | |
Primary | To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative | Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Proportion of barber-participant interactions that include delivery of the intervention | Week 13, Week 26, Week 39, Week 52, Week 65 | |
Secondary | To compare completion of self-initiated HIV testing between intervention and control groups | Consistent with this secondary study objective, the following endpoint will be assessed: Self-report of HIV test conducted between enrollment and study visit at Week 26, and between the Week 26 and Week 52 study visits | Week 26 and Week 52 | |
Secondary | To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition | Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including condom use | Week 26 and Week 52 | |
Secondary | To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition | Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including number of total sexual partners | Week 26 and Week 52 | |
Secondary | To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition | Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including number of new sexual partners | Week 26 and Week 52 | |
Secondary | To compare interest in or use of HIV prevention services between intervention and control groups | Consistent with this secondary study objective, the following endpoint will be assessed: Voluntary medical male circumcision (VMMC) during the study | Week 26 and Week 52 | |
Secondary | To compare interest in or use of HIV prevention services between intervention and control groups | Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported referral to PEP care or use of PEP | Week 26 and Week 52 | |
Secondary | To compare interest in or use of HIV prevention services between intervention and control groups | Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported referral to PrEP care or use of any PrEP method during the study | Week 26 and Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |